Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 10/15/2012 - 10/15/2013

This course is closed. Please look for other available products in CPNP University.

Target Audience

If you are a psychiatric or neurologic pharmacist or healthcare professional involved in the comprehensive medication management of patients with schizophrenia, we invite you to participate in this activity.

Activity Overview

This educational activity is offered by the College of Psychiatric and Neurologic Pharmacists in conjunction with Spire Learning.

Schizophrenia is a chronic, debilitating disorder in which successful long-term management represents a considerable clinical challenge. However, recent advances in the field are beginning to show promise toward enabling clinicians to render effective, personalized care. This activity will examine diagnostic tools for effective symptom assessment in schizophrenia and evolving theories on the pathogenesis of schizophrenia. The limitations of current antipsychotics will also be discussed, as well as the emergence of novel therapeutics with unique receptor binding profiles with the potential to improve patient outcomes.

Faculty Information and Disclosures

Deanna L. Kelly, PharmD, BCPP
Roger W. Sommi, PharmD, FCCP, BCPP
Steven C. Stoner, PharmD, BCPP
Elizabeth A. Winans, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

MODULE 1: Symptom Classification in Schizophrenia

  • Describe the presentation, diagnosis, and course of schizophrenia
  • Distinguish the key differences in the target symptoms of schizophrenia and evaluate the utility of rating scales for measuring illness domains

MODULE 2: Pathophysiology of Schizophrenia: Neurotransmitters, Receptors and Genetics

  • Examine the role of neurotransmitters and genetics in the pathogenesis of schizophrenia
  • Distinguish the roles of different receptor sites involved in schizophrenia

MODULE 3: Management of Schizophrenia

  • Review the relationship between receptor binding profiles of antipsychotic agents and adverse events
  • Evaluate the safety and efficacy of current antipsychotic agents in managing the symptoms of schizophrenia and the potential role of emerging therapies in improving patient health, well-being, and overall psychosocial functioning

MODULE 4: The Future of Schizophrenia Management

  • Describe the concepts of remission and recovery and their impact on optimal patient outcomes
  • Evaluate dopamine as a therapeutic target for schizophrenia and the emerging role of treatment strategies involving glutamate and glutamatergic modulation to optimize patient outcomes

Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each module will provide 0.5 contact hours (0.05 CEUs), for a total of 2 contact hours (0.2 CEUs) of knowledge-based continuing education credit. The ACPE universal program numbers assigned to this course are:  0284-000-12-046-H01-P (0.5 contact hours), 0284-000-12-047-H01-P (0.5 contact hours), 0284-000-12-048-H01-P (0.5 contact hours), and 0284-000-12-049-H01-P (0.5 contact hours).

Grant Support

This activity is supported by an educational grant from Genentech.